Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Health Economics & Reimbursement

LSD for Health Economics & Reimbursement

2 papers and 1 clinical trial exploring lsd as a treatment for health economics & reimbursement.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationApproximately 300 million individuals worldwide suffer from depression, with PTSD affecting about 7-8% of the US population at some point in their lives.

Health Economics & Reimbursement

Psychedelic-assisted therapies are gaining traction in the health economics domain, with promising findings regarding their efficacy in treating mental health disorders. As the FDA considers approval for compounds like MDMA and psilocybin, the economic implications, including reimbursement models, are increasingly relevant to healthcare systems worldwide.

Full Health Economics & Reimbursement profile

Academic Research

2 papers
Open Accessindividual

Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives

In a survey of 1,221 naturalistic psychedelic users, 76% judged altered states of consciousness to be very or extremely important for therapeutic effects, yet 61% said they would be willing to try a non-hallucinogenic analogue. Respondents considered about $70–80 per hour a reasonable fee for preparation, dosing and integration—substantially below current market projections for psychedelic-assisted psychotherapy.

Published
May 30, 2024
Journal
Journal of Psychedelic Studies
Authors
Aday, J. S., Boehnke, K. F., Herberholz, M., Kruger, D. J.
Paywallindividual

Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study

This trial (n=32) assessed the safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy adults within a novel intervention paradigm. Participants received 50 (n = 3), 75 (n = 7), 100 (n = 3) LSD, 50 µg followed by 75 µg LSD (n = 9) 1 week apart, or placebo followed by a 75 µg LSD (n = 10) 1 week apart. No serious adverse events were reported, This data indicates that LSD is safe and well-tolerated with mild adverse events reported.

Published
March 7, 2022
Journal
Journal of Psychopharmacology
Authors
Family, N., Hendricks, P. S., Williams, L. T. J., Luke, D., Krediet, E., Raz, S., Malliet, E. L.

Clinical Trials

1 trial
RecruitingPhase II

LSD to Improve Cluster Headache Impact Trial

This double-blind, placebo-controlled trial (n=65) will assess the efficacy and safety of LSD (25μg) every 3 days for 3 weeks versus placebo in treating chronic cluster headaches (CCH).

Started
January 1, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05477459

Explore further

Search all LSD papers Search all Health Economics & Reimbursement trials Full LSD profile Full Health Economics & Reimbursement profile